ESC 2014 Shines Spotlight On The Future Of Cardiology
The cardiology sector, long known as one of the most innovative in medtech, has a new wave of technologies on the horizon that could help reinvigorate the sector and create new multibillion-dollar market opportunities for device manufacturers. We take a closer look at these technologies, which include vagal nerve stimulation, remote monitoring for heart failure, as well as innovation in the percutaneous coronary intervention space, all of which were all in the spotlight at the recent European Society of Cardiology Congress 2014 in Barcelona.
The cardiology sector has long been one of the most innovative in medtech, with technologies such as drug-eluting stents (DES) and transcatheter aortic valves cutting down the need for more invasive open surgery.
A new wave of technologies is on the horizon, with the promise of treating heart failure patients who do not...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Daye is launching an at-home reproductive hormone testing service in the UK, utilizing a painless upper arm blood collection method. The product’s UKAS lab accreditation helps build credibility with healthcare providers.
EU4Health, the main funding instrument for EU health initiatives, has put renewed emphasis on orphan devices in its 2025 work program, published in July.
In return for building a successful US export business, Switzerland has been handed a 39% tariff effective immediately by the Trump administration. Diplomatic channels have been reopened to undo the tariff. Meanwhile, the medtech industry is looking to develop OUS markets for Swiss exporters.
HistoSonics’ CEO Michael Blue describes the deal as a win-win for all stakeholders and plans to use the money to expand clinical indications, as well as the global reach, for its Edison system.
Medical device firms often have serious compliance gaps, a recent Veeva MedTech survey found. Only 50% of the companies surveyed are confident in their global registration data, with 70% reporting inconsistencies during audits. The report recommends automation and better data governance.
The US FDA says PFAS used in medical devices are safe and that there’s no reason to restrict them in device production. An environmental group finds the agency’s assertion questionable.
EU4Health, the main funding instrument for EU health initiatives, has put renewed emphasis on orphan devices in its 2025 work program, published in July.
